National Cancer Institute, Research Contracts Branch, PSAS, 6120 Executive Blvd, EPS/Room 638, Bethesda, MD 20892-7227

A -- ATM GENE SEQUENCING IN SCANDINAVIAN AT PATIENTS AND THEIR RELATIVES SOL RFQ-NCI-80146-NV POC Debbie Moore, Purchasing Agent, 301-402-4509, Todd Cole, Contracting Officer, 301-402-4509 The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics Radiation Epidemiology Branch proposes to procure the services of Norwegian Radium Hospital, Department of Genetics, P.O. Box 56 Montabello, 0310 Oslo, Norway. The services of Norwegian Radium Hospital are needed to determine specific mutations in the ATM gene in Scandinavian families reporting at least one family member with Ataxia Telangiectasia (AT). Background: To identify specific mutations in the ATM gene, cell lines need to be established from blood samples and mutations that are screened and sequenced. Scandinavian families with AT are a unique resource in which to determine AT carrier status and specific mutation in the ATM gene because ATM is a rare autosomal, recessive syndrome in which patients develop cancer at a high rate . Specifications: This research requires sequencing genes from patients with ATM, their first degree relatives to determine the presence of a mutated ATM gene, and breast cancer patients from these families to determine if they also carry a mutated ATM gene. Mutations shall be identified in the ATM genes of approximately 14 AT family members, 40 first degree relatives and 22 breast cancer patients related to the AT patients. The techniques to be used shall include: 1) preparation of lymphocyte cell lines for the 14 members of AT affected families; 2) Constant Denaturing Gel Electrophoresis; 3) Protein Truncation Technique; 4) Restriction Endonuclease Fingerprinting; and 5) screening sequenced using the ABI 373 sequencer. For the first degree relatives, mutation analyses shall be performed to look for mutations already assigned to the proband in the family. Likewise, for the breast cancer patients, the mutation analyses shall be performed from tumor tissue from blocks. The information on mutations shall be recorded for each study subject and entered into the NCI study database. All data forms for the subjects whose lyphomcytes were screened and sequenced for mutations in the ATM gene shall be completed (including reasons for non-viability of any samples) and provided to the NCI Project Officer. This notice is a combined synopsis/solicitation and NCI does not intend to issue a separate solicitation. This solicitation, RFQ-NCI-80146-NV, has a Standard Industrial Classification Code of 8733, but is not set-aside for small business. Since a study sample of Scandinavian families already exist and there is previous, related data on the subjects, the Norwegian Radium Hospital is the only source known to NCI that can meet these requirements and maintain the reliability of the data. However, if any interested party believes it can meet the above specification, it may submit a statement of capabilities. Information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Capability statements must be received in the contracting office within 15 days after the publication date of this notice. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. (0154)

Loren Data Corp. http://www.ld.com (SYN# 0002 19980605\A-0002.SOL)